financetom
Business
financetom
/
Business
/
FDA Sets PDUFA Goal Date for Lexicon Pharmaceuticals' NDA Resubmission for Sotagliflozin
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
FDA Sets PDUFA Goal Date for Lexicon Pharmaceuticals' NDA Resubmission for Sotagliflozin
Jul 16, 2024 6:20 AM

08:51 AM EDT, 07/16/2024 (MT Newswires) -- Lexicon Pharmaceuticals ( LXRX ) said Tuesday the US Food and Drug Administration has set a Prescription Drug User Fee Act goal date of Dec. 20 for Zynquista as an adjunct to insulin therapy for glycemic control in adults with type 1 diabetes and chronic kidney disease.

The company said the FDA indicated that it considers the resubmission to be a complete response to the regulator's action letter in 2019 regarding the sotagliflozin NDA for type 1 diabetes.

"With a PDUFA date now in hand, we can begin the next phase of launch preparation for Zynquista," Chief Executive Mike Exton said in a statement.

Price: 2.0700, Change: -0.05, Percent Change: -2.36

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Copyright 2023-2025 - www.financetom.com All Rights Reserved